TY - JOUR
T1 - The role of intraoperative radiotherapy in pancreatic cancer
AU - Crane, Christopher H.
AU - Beddar, A. Sam
AU - Evans, Douglas B.
N1 - Funding Information:
This work was supported, in part, by grants PO1 CA-06294, T32CA77050, and P30CA16672 from the National Cancer Institute, US Department of Health and Human Services.
PY - 2003/10
Y1 - 2003/10
N2 - In single-institution studies, IORT at appropriate doses seems to safely improve local control in patients who have locally advanced pancreatic cancer, compared with historical controls. IORT also has been a component of adjuvant treatment programs that have led to excellent local control in resected patients. When considering the use of IORT, it is essential to have an understanding of the physical characteristics of the electron beam and how it can differ with the use of flat and beveled applicators. Although apparent improvement in local control with the use of IORT seems to have produced some improvement in median survival rates, high rates of distant failure continues to prevent a significant improvement in long-term survival. Because effective local control in patients with unresectable pancreatic cancer is a prerequisite to the development of curative therapies, the development of improved systemic therapies in patients with locally advanced pancreatic cancer will likely make local therapies such as the use of IORT even more important in the future.
AB - In single-institution studies, IORT at appropriate doses seems to safely improve local control in patients who have locally advanced pancreatic cancer, compared with historical controls. IORT also has been a component of adjuvant treatment programs that have led to excellent local control in resected patients. When considering the use of IORT, it is essential to have an understanding of the physical characteristics of the electron beam and how it can differ with the use of flat and beveled applicators. Although apparent improvement in local control with the use of IORT seems to have produced some improvement in median survival rates, high rates of distant failure continues to prevent a significant improvement in long-term survival. Because effective local control in patients with unresectable pancreatic cancer is a prerequisite to the development of curative therapies, the development of improved systemic therapies in patients with locally advanced pancreatic cancer will likely make local therapies such as the use of IORT even more important in the future.
UR - http://www.scopus.com/inward/record.url?scp=0345449065&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0345449065&partnerID=8YFLogxK
U2 - 10.1016/S1055-3207(03)00090-5
DO - 10.1016/S1055-3207(03)00090-5
M3 - Review article
C2 - 14989127
AN - SCOPUS:0345449065
SN - 1055-3207
VL - 12
SP - 965
EP - 977
JO - Surgical oncology clinics of North America
JF - Surgical oncology clinics of North America
IS - 4
ER -